Welcome to our dedicated page for Rubius Therapeutics news (Ticker: RUBY), a resource for investors and traders seeking the latest updates and insights on Rubius Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rubius Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rubius Therapeutics's position in the market.
Rubius Therapeutics (Nasdaq: RUBY) announced the completion of the first dosing cohort in its Phase 1/2 clinical trial for RTX-240, an allogeneic therapy for relapsed/refractory solid tumors, with no adverse events reported. The trial will assess immune responses, including NK and T cell activation, and measure anti-tumor activity. Additionally, the company will undergo a management transition as CFO Andrew Oh departs by December 31, 2020, after significantly contributing to capital raising and securing clinical supplies.
Rubius Therapeutics (Nasdaq: RUBY) presented promising preclinical data for RTX-321, its lead artificial antigen-presenting cell therapy for HPV 16-positive cancers, at the AACR Virtual Annual Meeting II. These findings suggest RTX-321 may promote epitope spreading, potentially enhancing immune responses against tumor antigens. Additionally, RTX-321 shows promise in inducing tumor-specific memory, which could provide long-term protection against recurrence. The company plans to file an Investigational New Drug application for RTX-321 by the end of 2020, signaling its commitment to advancing this innovative treatment.
Rubius Therapeutics (Nasdaq: RUBY) announced that CEO Pablo J. Cagnoni, M.D. will engage in a fireside chat at the Jefferies Virtual 2020 Healthcare Conference on June 2, 2020, at 1:00 p.m. ET. The session will focus on the company's development of a new class of cellular medicines known as Red Cell Therapeutics™, aimed at treating cancer and autoimmune diseases. A live audio webcast of the event will be available on the company’s website, along with an archived replay for 90 days post-event.
Rubius Therapeutics (Nasdaq: RUBY) announced plans to present preclinical data on its artificial antigen-presenting cell program, RTX-321, targeting HPV 16-positive cancers at the AACR Virtual Annual Meeting II from June 22-24, 2020. Laurence Turka, M.D., highlighted that HPV 16 is linked to 70% of cervical cancers and significant head and neck cancers, showcasing the unmet need for innovative therapies. Data will demonstrate RTX-321's ability to activate tumor-specific T cells and stimulate anti-tumor responses, with an Investigational New Drug application expected by year-end 2020.
Rubius Therapeutics (RUBY) presented promising preclinical data for RTX-321, targeting HPV 16-positive tumors, at the American Society of Gene and Cell Therapy Annual Meeting. The data showed significant expansion of effector and memory CD8+ T cells, crucial for effective anti-tumor immune responses. Additionally, RTX-321 can enhance both naïve and exhausted CD4+ T cells, which play a vital role in coordinating immune responses. The company plans to file an Investigational New Drug application for RTX-321 by the end of 2020, marking a critical step in its therapeutic development.
Rubius Therapeutics, Inc. (Nasdaq:RUBY) announced a strategic reprioritization of its pipeline to focus on oncology and autoimmune therapies. The company dosed its first patient in the Phase 1/2 trial of RTX-240 for advanced solid tumors. With an operational manufacturing facility and a cash position of $241.4 million, Rubius has sufficient resources to sustain operations into 2022. The first quarter 2020 net loss was $48.5 million, up from $32.6 million in Q1 2019, primarily due to increased R&D investments.
Rubius Therapeutics (Nasdaq: RUBY) announced the dosing of its first patient in the Phase 1/2 clinical trial of RTX-240, aimed at treating relapsed/refractory or locally advanced solid tumors. RTX-240 is an allogeneic Red Cell Therapeutic designed to stimulate immune responses against tumors. The study will evaluate safety, tolerability, and pharmacodynamics, with a focus on NK and T cell activation. The company is collaborating with oncology-focused centers to maximize patient enrollment while maintaining safety standards amid the COVID-19 pandemic.
Rubius Therapeutics (Nasdaq:RUBY) will announce its first quarter 2020 financial results on May 11, 2020, before the market opens. The company specializes in genetically engineered red blood cells to develop Red Cell Therapeutics™ for treating various diseases, notably cancer and autoimmune conditions. Notably, Rubius will not hold a teleconference following the release of its financial results. The company utilizes its proprietary RED PLATFORM® to create off-the-shelf therapies aimed at specific therapeutic areas. For more details, visit www.rubiustx.com.